Get the Stockscreener App
101.32
8.37%
-9.25
After Hours:
102.92
1.60
+1.58%
Inhibrx Biosciences Inc stock is traded at $101.32, with a volume of 552.88K.
It is down -8.37% in the last 24 hours and down -11.96% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$110.57
Open:
$111.15
24h Volume:
552.88K
Relative Volume:
1.43
Market Cap:
$1.49B
Revenue:
$1.30M
Net Income/Loss:
$-140.06M
P/E Ratio:
-11.20
EPS:
-9.0441
Net Cash Flow:
$-129.83M
1W Performance:
-6.74%
1M Performance:
-11.96%
6M Performance:
+20.72%
1Y Performance:
+707.97%
1-Day Range:
$99.00
$111.15
1-Week Range:
$99.00
$113.95
52-Week Range:
$12.24
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
101.32 | 1.62B | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Inhibrx Biosciences (INBX) price target increased by 66.67% to 255.00 - MSN
Inhibrx Inc stock (US45720L1070): trial update around ozekibart keeps biotech investors watching - AD HOC NEWS
TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Greater China Plan Under Evaluation - AASTOCKS.com
Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study - MSN
Inhibrx Biosciences, Inc.Common Stock (NQ: INBX - The Chronicle-Journal
This biotech stock surges after positive cancer trial results. What to know. - MSN
Liquidity Mapping Around (INBX) Price Events - Stock Traders Daily
Inhibrx cancer treatment shows high response rates in head and neck cancer study - MSN
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230 - Moomoo
Viking Global holds 1.46M shares in Inhibrx (INBX); amendment removes one reporter - Stock Titan
Perceptive (INBX) reports a 9.99% stake in INHIBRx via Schedule 13G/A - Stock Titan
Inhibrx Biosciences 1Q Loss/Shr $2.15 >INBX - Moomoo
Inhibrx Reports First Quarter 2026 Financial Results - Arizona Daily Sun
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $325 - Moomoo
Inhibrx & Invesco Mortgage Capital Q1 2026 Results - Punjab Kesari English
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer - BioPharma APAC
Inhibrx Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibrx Biosciences (INBX) cuts Q1 2026 loss, boosts cash but ups debt - Stock Titan
Inhibrx Biosciences (INBX) advances ozekibart BLA and INBRX-106 after strong oncology data - Stock Titan
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study - Insider Monkey
Inhibrx Inc stock (US45720L1070): Biotech firm in Virtus ETF holdings - AD HOC NEWS
Inhibrx seeks FDA OK for cancer drug as Q1 loss totals $33.4M - Stock Titan
INBX Stock Price, Quote & Chart | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors? - Yahoo Finance
Inhibrx Biosciences (INBX) Stock Jumps 17% on Positive Cancer Trial Results - MEXC Exchange
Inhibrx Biosciences (INBX) Stock Soars 17% Following Impressive Phase 2 Cancer Data - MEXC Exchange
This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know. -- Barrons.com - Moomoo
Inhibrx Biosciences Reports Positive Interim Phase 2 Results - TipRanks
INBRX106 trial update signals pipeline progress at Inhibrx Biosciences - Traders Union
INBRX-106 boosts response in HNSCC for Inhibrx (Nasdaq: INBX) with Phase 2 results - Stock Titan
Inhibrx Biosciences (NASDAQ:INBX) Shares Gap UpHere's What Happened - MarketBeat
Why Is Inhibrx Biosciences Stock Trading Higher Today?Inhibrx Biosciences (NASDAQ:INBX) - Benzinga
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Inhibrx reports interim phase 2 data for cancer drug trial - Investing.com UK
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study - Barchart.com
Inhibrx Biosciences Stock Rises After Positive Cancer Trial Results. What to Know. - Barron's
This Biotech Stock Surges After Positive Cancer Trial Results. What to Know. -- Barrons.com - Moomoo
TradingKey - TradingKey
Inhibrx Biosciences (INBX) Shares Surge 17% Following Promising Head and Neck Cancer Data - parameter.io
Inhibrx Biosciences (INBX) Shares Soar 17% Following Promising Phase 2 Cancer Study Data - MoneyCheck
Inhibrx Biosciences reports positive Ph2 trial data, stock gains By Investing.com - Investing.com Nigeria
Inhibrx Biosciences reports positive Ph2 trial data, stock gains - Investing.com India
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):